Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1015

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 1015
---
 reflect the 1:5 Reverse Stock Split (and the 1:12 Reverse Stock Split in August 2024), including
reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.

Other Events

On January 8, 2025 and January 29, 2025, the
Company issued 296,400 shares and 88,800 shares of common stock, respectively upon the exercise of 296,400 and 88,800 September 2024
Pre-Funded Warrants, respectively, resulting in aggregate cash proceeds to the Company of $1,926.

On January 20, 2025, the Company issued a total
of 15,809 shares of common stock to certain executives and consultants, in settlement of the share-based portion of the 2024 performance
bonuses as discussed in Note 10, based on the closing price of the Company’s common stock on January 2, 2025. Approximately 2,748
shares were withheld to cover payroll tax withholdings.

On January 28, 2025, the Company announced the
approval of an Investigational Review Board (IRB) sanctioned Phase II clinical study. The study (NCT06656351) will evaluate the efficacy
and safety of the tafenoquine for treating patients with a presumptive diagnosis of chronic babesiosis, the patient enrollment of which
is expected to begin in the third quarter of 2025.

There have been no other events or transactions
during this time which would have a material effect on these consolidated financial statements.

F-37

Item 9. Changes in and Disagreements with Accountants
on Accounting and Financial Disclosure.

None.

Item 9A. Controls and
Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures,
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures
designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls
and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us
in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal
executive officer and